公开(公告)号：US20090163520A1

公开(公告)日：2009-06-25

申请号：US11722484

申请日：2005-12-22

Applicant: Thomas Stephen Coulter ,  Stephen Taylor ,  Stephen Murfin ,  Valery Thammalaksa ,  Babette Aicher ,  Stefan Jaekel ,  Tanja Reuter

Inventor： Thomas Stephen Coulter ,  Stephen Taylor ,  Stephen Murfin ,  Valery Thammalaksa ,  Babette Aicher ,  Stefan Jaekel ,  Tanja Reuter

IPC: A61K31/519 ,  C07D487/04 ,  A61P3/10

CPC classification number: A61K31/519

Abstract: The present invention relates to the use of pyrazolopyrimidine compounds for the production of pharmaceutical compositions for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2a or Mnk2b) and/or variants thereof.

Abstract translation: 本发明涉及吡唑并嘧啶化合物用于生产药物组合物用于预防和/或治疗可受到抑制Mnk1和/或Mnk2（Mnk2a或Mnk2b）的激酶活性和/或 其变体。

公开(公告)号：US08071607B2

公开(公告)日：2011-12-06

申请号：US11722484

申请日：2005-12-22

Applicant: Thomas Stephen Coulter ,  Steven Taylor ,  Stephen Murfin ,  Valery Thammalaksa ,  Babette Aicher ,  Stefan Jaekel ,  Tanja Reuter

Inventor： Thomas Stephen Coulter ,  Steven Taylor ,  Stephen Murfin ,  Valery Thammalaksa ,  Babette Aicher ,  Stefan Jaekel ,  Tanja Reuter

IPC: A01N43/90 ,  A61K31/519

CPC classification number: A61K31/519

Abstract: The present invention relates to the use of pyrazolopyrimidine compounds for the production of pharmaceutical compositions for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2a or Mnk2b) and/or variants thereof.

Abstract translation: 本发明涉及吡唑并嘧啶化合物用于生产药物组合物用于预防和/或治疗可受到抑制Mnk1和/或Mnk2（Mnk2a或Mnk2b）的激酶活性和/或 其变体。

公开(公告)号：US20100056548A1

公开(公告)日：2010-03-04

申请号：US12296427

申请日：2007-04-10

Applicant: Babette Aicher ,  Thomas Stephen Coulter ,  Stefan Jaekel ,  Arndt-René Kelter ,  Stephen Murfin ,  Tanja Reuter ,  Steven Taylor

Inventor： Babette Aicher ,  Thomas Stephen Coulter ,  Stefan Jaekel ,  Arndt-René Kelter ,  Stephen Murfin ,  Tanja Reuter ,  Steven Taylor

IPC: A61K31/519 ,  C07D495/04 ,  A61P3/00 ,  A61P35/00 ,  A61P3/10 ,  A61P3/04 ,  A61P9/12 ,  A61P9/00 ,  A61P29/00

CPC classification number: C07D495/04

Abstract: The present invention relates to novel pharmaceutical compositions comprising thienopyrimidine compounds. Moreover, the present invention relates to the use of the thienopyrimidine compounds of the invention for the production of pharmaceutical compositions for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2a or Mnk2b) and/or variants thereof.

Abstract translation: 本发明涉及包含噻吩并嘧啶化合物的新型药物组合物。 此外，本发明涉及本发明的噻吩并嘧啶化合物用于生产药物组合物用于预防和/或治疗可受到抑制Mnk1和/或Mnk2（Mnk2a）激酶活性的疾病的用途 或Mnk2b）和/或其变体。

公开(公告)号：US08697713B2

公开(公告)日：2014-04-15

申请号：US12373224

申请日：2007-07-10

Applicant: Stefan Jäkel ,  Tanja Reuter ,  Stephen Murfin ,  Thomas Stephen Coulter ,  Steven Taylor

Inventor： Stefan Jäkel ,  Tanja Reuter ,  Stephen Murfin ,  Thomas Stephen Coulter ,  Steven Taylor

IPC: A01N43/90 ,  A61K31/519 ,  C07D487/00

CPC classification number: C07D487/04

Abstract: The present invention relates to novel pyrrolopyrimidine compounds of the general formula (1) and pharmaceutical compositions comprising said pyrrolopyrimidine compounds. Moreover, the present invention relates to the use of the pyrrolopyrimidine compounds of the invention for the production of pharmaceutical compositions for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2a or Mnk2b) and/or variants thereof.

Abstract translation: 本发明涉及通式（1）的新型吡咯并嘧啶化合物和包含所述吡咯并嘧啶化合物的药物组合物。 此外，本发明涉及本发明的吡咯并嘧啶化合物用于制备药物组合物用于预防和/或治疗可受到抑制Mnk1和/或Mnk2（Mnk2a）激酶活性的疾病的用途 或Mnk2b）和/或其变体。

公开(公告)号：US08633201B2

公开(公告)日：2014-01-21

申请号：US12296427

申请日：2007-04-10

Applicant: Babette Aicher ,  Thomas Stephen Coulter ,  Stefan Jaekel ,  Arndt-René Kelter ,  Stephen Murfin ,  Tanja Reuter ,  Steven Taylor

Inventor： Babette Aicher ,  Thomas Stephen Coulter ,  Stefan Jaekel ,  Arndt-René Kelter ,  Stephen Murfin ,  Tanja Reuter ,  Steven Taylor

IPC: C07D495/04 ,  A61K31/519 ,  A61P19/02 ,  A61P17/06 ,  A61P11/06 ,  A61P29/00

CPC classification number: C07D495/04

Abstract: The present invention relates to novel pharmaceutical compositions comprising thienopyrimidine compounds. Moreover, the present invention relates to the use of the thienopyrimidine compounds of the invention for the production of pharmaceutical compositions for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2a or Mnk2b) and/or variants thereof.

Abstract translation: 本发明涉及包含噻吩并嘧啶化合物的新型药物组合物。 此外，本发明涉及本发明的噻吩并嘧啶化合物用于生产药物组合物用于预防和/或治疗可受到抑制Mnk1和/或Mnk2（Mnk2a）激酶活性的疾病的用途 或Mnk2b）和/或其变体。

公开(公告)号：US20100105708A1

公开(公告)日：2010-04-29

申请号：US12373224

申请日：2007-07-10

Applicant: Stefan Jäkel ,  Tanja Reuter ,  Stephen Murfin ,  Thomas Stephen Coulter ,  Steven Taylor

Inventor： Stefan Jäkel ,  Tanja Reuter ,  Stephen Murfin ,  Thomas Stephen Coulter ,  Steven Taylor

IPC: A61K31/519 ,  C07D487/04 ,  A61P3/00 ,  A61P29/00

CPC classification number: C07D487/04

Abstract: The present invention relates to novel pyrrolopyrimidine compounds of the general formula (1) and pharmaceutical compositions comprising said pyrrolopyrimidine compounds. Moreover, the present invention relates to the use of the pyrrolopyrimidine compounds of the invention for the production of pharmaceutical compositions for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2a or Mnk2b) and/or variants thereof.

Abstract translation: 本发明涉及通式（1）的新型吡咯并嘧啶化合物和包含所述吡咯并嘧啶化合物的药物组合物。 此外，本发明涉及本发明的吡咯并嘧啶化合物用于制备药物组合物用于预防和/或治疗可受到抑制Mnk1和/或Mnk2（Mnk2a）激酶活性的疾病的用途 或Mnk2b）和/或其变体。